MiMedx re­ceives FDA warn­ing let­ter over Ax­iofill man­u­fac­tur­ing con­cerns

The FDA has high­light­ed de­vi­a­tions from cur­rent good man­u­fac­tur­ing prac­tice for MiMedx’s Ax­iofill, a pla­cen­ta-based prod­uct which is un­der re­view re­gard­ing its le­gal clas­si­fi­ca­tion. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER